MA42312A - Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine - Google Patents

Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine

Info

Publication number
MA42312A
MA42312A MA042312A MA42312A MA42312A MA 42312 A MA42312 A MA 42312A MA 042312 A MA042312 A MA 042312A MA 42312 A MA42312 A MA 42312A MA 42312 A MA42312 A MA 42312A
Authority
MA
Morocco
Prior art keywords
virus
type particles
gag protein
bovine immunodeficiency
immunodeficiency virus
Prior art date
Application number
MA042312A
Other languages
English (en)
Inventor
Peter Pushko
Irina Tretyakova
Original Assignee
Medigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Inc filed Critical Medigen Inc
Publication of MA42312A publication Critical patent/MA42312A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
MA042312A 2015-07-02 2016-07-01 Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine MA42312A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562188084P 2015-07-02 2015-07-02

Publications (1)

Publication Number Publication Date
MA42312A true MA42312A (fr) 2018-05-09

Family

ID=57609369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042312A MA42312A (fr) 2015-07-02 2016-07-01 Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine

Country Status (14)

Country Link
US (2) US11576965B2 (fr)
EP (1) EP3316906A4 (fr)
JP (2) JP6978079B2 (fr)
KR (1) KR20180032586A (fr)
CN (2) CN108348596B (fr)
BR (1) BR112018000037A2 (fr)
CA (1) CA2991213A1 (fr)
EA (1) EA201890187A1 (fr)
HK (1) HK1259067A1 (fr)
MA (1) MA42312A (fr)
MX (1) MX2018000023A (fr)
PE (1) PE20180771A1 (fr)
RU (2) RU2734118C2 (fr)
WO (1) WO2017004586A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018000037A2 (pt) * 2015-07-02 2018-09-04 Medigen Inc partículas semelhantes a vírus recombinantes usando a proteína gag do vírus da imunodeficiência bovina (vlp de bgag), vacina, vetor plasmidial de transferência para produzir a vlp de bgag, método para fazer a vlp de bgag, método para preparar a vacina
CN112279900A (zh) * 2020-12-30 2021-01-29 乾元浩生物股份有限公司 H9n2亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864085B2 (en) * 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
US20060088909A1 (en) 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
DE60335139D1 (de) * 2002-05-17 2011-01-05 Univ Emory Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US20100143406A1 (en) * 2006-06-30 2010-06-10 Gale Smith Methods of enhancing protein incorporation into virus like particles
JP2009544322A (ja) 2006-07-27 2009-12-17 リゴサイト ファーマシューティカルズ インコーポレイテッド キメラウイルス様粒子
CN101668857A (zh) * 2007-02-21 2010-03-10 诺瓦瓦克斯股份有限公司 嵌合的新城疫病毒vlp
JP2010528613A (ja) 2007-05-29 2010-08-26 クリストファー ビー． リード， 多能細胞集団を産生する方法およびその使用
KR20100063030A (ko) * 2007-07-19 2010-06-10 노바백스, 인코포레이티드 바리셀라 조스터 바이러스-바이러스 유사 입자(ＶＬＰｓ) 및 항원
WO2011087839A1 (fr) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccin contre le virus de la grippe a
EP2575773A4 (fr) * 2010-05-26 2014-06-25 Selecta Biosciences Inc Vaccins polyvalents à nanovéhicules synthétiques
CN102676461A (zh) * 2011-03-17 2012-09-19 中国科学院上海巴斯德研究所 一种利用果蝇细胞生产病毒样颗粒的方法及应用
WO2015066715A1 (fr) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Pseudo-particules virales et procédés qui leur sont associés
BR112018000037A2 (pt) * 2015-07-02 2018-09-04 Medigen Inc partículas semelhantes a vírus recombinantes usando a proteína gag do vírus da imunodeficiência bovina (vlp de bgag), vacina, vetor plasmidial de transferência para produzir a vlp de bgag, método para fazer a vlp de bgag, método para preparar a vacina

Also Published As

Publication number Publication date
CN108348596A (zh) 2018-07-31
MX2018000023A (es) 2018-08-15
EP3316906A1 (fr) 2018-05-09
CN115927212A (zh) 2023-04-07
CN108348596B (zh) 2022-08-23
JP2018525028A (ja) 2018-09-06
HK1259067A1 (zh) 2019-11-22
RU2757723C2 (ru) 2021-10-21
RU2018103757A3 (fr) 2019-12-09
RU2020125098A3 (fr) 2020-12-11
RU2018103757A (ru) 2019-08-05
JP2020198893A (ja) 2020-12-17
BR112018000037A2 (pt) 2018-09-04
PE20180771A1 (es) 2018-05-07
US11576965B2 (en) 2023-02-14
RU2020125098A (ru) 2020-09-04
CA2991213A1 (fr) 2017-01-05
JP6978079B2 (ja) 2021-12-08
RU2734118C2 (ru) 2020-10-13
EP3316906A4 (fr) 2019-01-02
US20180369364A1 (en) 2018-12-27
WO2017004586A1 (fr) 2017-01-05
KR20180032586A (ko) 2018-03-30
EA201890187A1 (ru) 2018-06-29
US20230310579A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
MA44077A (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
IL263801B1 (en) Novel adeno-associated virus capsid proteins
MA40824A (fr) Particules de cmv de type virus modifié
MA47323A (fr) Protéines de liaison icos
MA41421A (fr) Anticorps humains contre la glycoprotéine du virus ebola
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
MA43660A (fr) Anticorps anti-facteur xi de coagulation
EP3471767A4 (fr) Hémagglutinines du virus de la grippe et utilisations de celles-ci
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
DK3143138T3 (da) Betinget aktive biologiske proteiner
HK1259067A1 (zh) 用牛免疫缺陷病毒gag蛋白的重組病毒樣顆粒
IL285146A (en) Methods for purifying proteins involving FC
MA45234A (fr) Anticorps anti-facteur xi de coagulation
EP3770604A3 (fr) Procédé de cytométrie de flux pour évaluer dans un matériel biologique des particules de taille virale non associées d'un type viral du virus de la grippe
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
MA43925A (fr) Procã‰dã‰s de traitement du virus de l'hã‰patite b
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
WO2014152946A3 (fr) Polypeptides pour le traitement et/ou la limitation d'une infection grippale
CL2022000902A1 (es) Virus del moquillo canino hemaglutinina y polipéptidos de fusión
DK3469071T3 (da) Herpesvirus med modificeret glycoprotein D
DK3271724T3 (da) Anvendelse af en standard til påvisning af proteinaggregater i en proteinfejlfoldningssygdom